LCZ696
Cat. No.：YN321181
CAS No. ：936623-90-4
| 产品名称: | LCZ696 |
| CAS No.: | 936623-90-4 |
| Chemical Name: | N-(1-oxopentyl)-N-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-L-valine compd. with α-ethyl (αR,γS)-γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl[1,1’-biphenyl]-4-pentanoate, sodium salt, hydrate (2:2:6:5) |
| Synonyms: | Sacubitril/Valsartan |
| 分子量: | 957.99 |
| 分子式: | C₄₈H₆₀N₆Na₃O₁₀.₅ |
| SMILES: | O=C(CCC(O[Na])=O)N([C@H](CC(C=C1)=CC=C1C2=CC=CC=C2)C[C@@H](C)C(OCC)=O)[H].O=C(O[Na])[C@@H](N(C(CCCC)=O)CC3=CC=C(C4=CC=CC=C4C5=NN=NN5[Na])C=C3)C(C)C.[2.5H2O] |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | LCZ696 (Sacubitril/Valsartan) 是由 Valsartan (an ARB) 和 Sacubitril (AHU377) 组成，摩尔比为 1:1，是一种首创的，口服生物可利用的双作用血管紧张素受体(ARN)抑制剂，用于研究高血压和心力衰竭。LCZ696 可通过抑制炎症、氧化应激和细胞凋亡来改善糖尿性心肌病。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Burnier, M.Angiotensin II type 1 receptor blockersCirculation103(6),904-912(2001)
Schiering, N., D'Arcy, A., Villard, F., et al.Structure of neprilysin in complex with the active metabolite of sacubitrilSci. Rep.6,27909(2016)
Gu, J., Noe, A., Chandra, P., et al.Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)J. Clin. Pharmacol.50(4),401-414(2010)
